menu
    • menu

    Company profile for Memo Therapeutics

    NEW Drugs in Dev: 5
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Exploiting the power of our microfluidic single-cell molecular cloning and screening technologies we engage in antibody discovery across species and indications for proprietary and partnered projects. Our current pipeline features programmes in infectious diseases and immuno-oncology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Memo TherapeuticsSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Wagistrasse 27, 8952 Schlieren
    Telephone
    Telephone
    +41 44 515 91 40
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://memo-therapeutics.com/home.html
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Memo Therapeutics AG Releases Bkpyv Infection Study
    Memo Therapeutics AG Releases Bkpyv Infection Study

    09 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/09/3216009/0/en/Memo-Therapeutics-AG-Publishes-BKPyV-Infection-Disease-Burden-Study-in-the-Journal-of-Patient-Reported-Outcomes.html

    GLOBENEWSWIRE
    09 Jan 2026
    Share Share
    Memo Therapeutics AG's Potravitug Receives Orphan Designation
    Memo Therapeutics AG's Potravitug Receives Orphan Designation

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207550/0/en/Memo-Therapeutics-AG-s-Potravitug-Granted-Orphan-Designation-in-the-European-Union.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Memo Therapeutics AG Unveils SAFE KIDNEY Trial Data at ASN
    Memo Therapeutics AG Unveils SAFE KIDNEY Trial Data at ASN

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183523/0/en/Memo-Therapeutics-AG-Presents-Long-Term-Follow-Up-Data-from-its-Phase-II-SAFE-KIDNEY-Trial-of-Potravitug-and-Real-World-Data-on-the-Challenges-and-Re-source-Utilization-of-Managing.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Memo Phase I Study on BKPyV Infection Neutralizing Antibody
    Memo Phase I Study on BKPyV Infection Neutralizing Antibody

    19 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/19/3135566/0/en/Memo-Therapeutics-AG-Publishes-Phase-I-Safety-Tolerability-and-Pharmacokinetics-Study-for-Neutralizing-Antibody-Targeting-BKPyV-Infection-in-Clinical-and-Translational-Science.html

    GLOBENEWSWIRE
    19 Aug 2025
    Share Share
    Memo Pushes Kidney Drug to Phase 3 Despite Primary Endpoint Miss
    Memo Pushes Kidney Drug to Phase 3 Despite Primary Endpoint Miss

    25 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/25/3121720/0/en/Memo-Therapeutics-AG-Announces-Phase-II-Trial-Results-for-Potravitug-in-Kidney-Transplant-Recipients-with-BKPyV-Infection.html

    GLOBENEWSWIRE
    25 Jul 2025
    Share Share
    Memo Therapeutics AG's Potent Antibody for BKPyV Infection
    Memo Therapeutics AG's Potent Antibody for BKPyV Infection

    22 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/22/3119272/0/en/Memo-Therapeutics-AG-Publishes-Study-on-its-Potent-Antibody-for-Treatment-of-BKPyV-Infection-in-Kidney-Transplantation.html

    GLOBENEWSWIRE
    22 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search